In the BioHarmony Drug Report Database

"Preview" Icon

Deoxycholic acid

Kybella, Chenodeoxycholic acid Leadiant, Chenodeoxycholic acid sigma-tau (deoxycholic acid) is a small molecule pharmaceutical. Deoxycholic acid was first approved as Kybella on 2015-04-29. It has been approved in Europe to treat cerebrotendinous xanthomatosis and inborn errors metabolism. It is known to target fMet-Leu-Phe receptor, G-protein coupled bile acid receptor 1, and multidrug efflux RND transporter permease subunit. Kybella’s patents are valid until 2030-03-02 (FDA).


Trade Name


Chenodeoxycholic acid Leadiant, known as Chenodeoxycholic acid sigma-tau

Common Name


deoxycholic acid






cerebrotendinous xanthomatosis, inborn errors metabolism

Drug Class


Image (chem structure or protein)

Deoxycholic acid structure rendering